Toxoplasmosis Treatment Drugs Global Market Report 2026
상품코드:1957879
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
톡소플라즈마증 치료제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 34억 9,000만 달러에서 2026년에는 36억 7,000만 달러에 이르고, CAGR 5.3%로 성장할 전망입니다. 지난 수년간의 성장은 톡소플라즈마 감염증의 확산, 제한된 치료 옵션, 의료 종사자들의 인식 제고, 병원 약국 유통 확대, 재래식 제제 채택 등이 주요 요인으로 꼽힙니다.
톡소플라즈마증 치료제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 46억 6,000만 달러에 이르고, CAGR은 6.1%를 나타낼 전망입니다. 예측 기간의 성장에는 정밀의료의 발전, 항기생충제 연구개발 투자 증가, 온라인 약국 확대, 면역 결핍 환자 증가, 새로운 병용요법 도입 등이 요인으로 작용할 것으로 보입니다. 예측 기간 동안 주요 동향으로는 항기생충제 개발 연구 증가, 병용요법에 대한 수요 증가, 소아 및 면역 결핍 환자 치료 확대, 병원 및 온라인 약국 유통 채널 확대, 경구제 및 주사제 제형 개발 등을 들 수 있습니다.
톡소플라즈마 감염증의 유병률 증가는 향후 몇 년 동안 톡소플라즈마 치료제 시장의 성장을 견인할 것으로 예측됩니다. 톡소플라즈마증은 원충 기생충 톡소플라즈마 곤디이에 의한 인간과 동물의 감염 질환입니다. 감염자 수가 증가함에 따라 특정 톡소플라즈마증 치료에 사용되는 피리메타민, 스피라마이신, 류코볼린 등의 약제 수요가 증가하여 시장을 주도하고 있습니다. 예를 들어, 영국 정부 기관인 영국 보건안전청 자료에 따르면, 2024년 2월 기준 2023년 2분기에 확인된 톡소플라즈마증 사례는 54건으로 2022년 같은 기간의 37건보다 증가하였습니다. 따라서 톡소플라즈마증 유병률 증가는 톡소플라즈마증 치료제 시장 확대에 기여하고 있습니다.
톡소플라즈마증 치료제 시장의 주요 기업들은 시장에서의 입지를 강화하기 위해 전략적 투자에 집중하고 있습니다. 전략적 투자란 경쟁 우위 확보, 신규 시장 진출, 신기술 개발 등 장기적인 목표 달성을 위해 자원을 배분하는 것을 의미합니다. 예를 들어, 2023년 4월 영국에 본사를 둔 의약품 개발 기업 ASTRA Therapeutics는 말라리아, 크립토스포리디움증, 톡소플라즈마증 등 전 세계 수백만 명에게 영향을 미치고 가축과 농업에 막대한 손실을 초래하는 기생충 질환의 치료법 개발을 추진하기 위해 15만 스위스프랑(17만 3,787달러)의 자금 조달을 확보했습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Toxoplasmosis treatment drugs are medications used to manage infections caused by Toxoplasma gondii. They treat the parasitic infection that can result from exposure to cat feces or contaminated food.
The main drug classes in the toxoplasmosis treatment market include pyrimethamine, spiramycin, leucovorin, sulfadiazine, folic acid, and others. Chronic toxoplasmosis refers to long-term infection caused by the Toxoplasma gondii parasite. These drugs are indicated for both chronic and acute toxoplasmosis infections. Administration routes include oral and parenteral, and they are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
Tariffs have influenced the toxoplasmosis treatment drugs market by increasing the cost of imported raw materials and active pharmaceutical ingredients, leading to higher production costs. The parenteral and oral drug segments, particularly in regions like North America and Europe that rely on global supply chains, are most affected. While tariffs have created cost pressures, they have also incentivized local manufacturing and domestic sourcing, potentially boosting regional production capabilities and innovation in combination therapies.
The toxoplasmosis treatment drugs market research report is one of a series of new reports from The Business Research Company that provides toxoplasmosis treatment drugs market statistics, including toxoplasmosis treatment drugs industry global market size, regional shares, competitors with a toxoplasmosis treatment drugs market share, detailed toxoplasmosis treatment drugs market segments, market trends and opportunities, and any further data you may need to thrive in the toxoplasmosis treatment drugs industry. This toxoplasmosis treatment drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The toxoplasmosis treatment drugs market size has grown strongly in recent years. It will grow from $3.49 billion in 2025 to $3.67 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to prevalence of toxoplasmosis infections, limited treatment options, growing awareness among healthcare providers, increased hospital pharmacy distribution, adoption of conventional drug formulations.
The toxoplasmosis treatment drugs market size is expected to see strong growth in the next few years. It will grow to $4.66 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to advancements in precision medicine, rising investment in anti-parasitic drug R&D, expansion of online pharmacies, growing immunocompromised patient population, introduction of novel combination therapies. Major trends in the forecast period include increased research in anti-parasitic drug development, rising demand for combination therapies, growth in pediatric and immunocompromised patient treatments, expansion of hospital and online pharmacy distribution channels, development of oral and parenteral formulations.
The rising prevalence of toxoplasmosis infections is expected to drive the growth of the toxoplasmosis treatment drug market in the coming years. Toxoplasmosis is an infection caused by the protozoan parasite Toxoplasma gondii in humans and animals. The increasing number of infections fuels demand for drugs such as pyrimethamine, spiramycin, and leucovorin, which are used to treat specific types of toxoplasmosis, thereby boosting the market. For example, in February 2024, according to data from the UK Health Security Agency, a UK-based government organization, 54 confirmed cases of toxoplasmosis were reported in the second quarter of 2023, up from 37 cases in the same period of 2022. Consequently, the rising prevalence of toxoplasmosis is contributing to the expansion of the toxoplasmosis treatment drug market.
Key companies in the toxoplasmosis treatment drug market are focusing on strategic investments to strengthen their market position. Strategic investments involve allocating resources to achieve long-term goals such as gaining competitive advantage, entering new markets, or developing new technologies. For instance, in April 2023, ASTRA Therapeutics, a UK-based drug development company, secured CHF 150,000 ($173,787) in funding to advance therapies for parasitic diseases, including malaria, cryptosporidiosis, and toxoplasmosis, which affect millions globally and cause significant losses in livestock and agriculture.
In August 2023, Vyera Pharmaceuticals, LLC, a Switzerland-based pharmaceutical company, entered into an asset purchase agreement with Phoenixus AG for an undisclosed amount. Under this agreement, the companies planned to sell rights to Daraprim, a prescription drug containing pyrimethamine used to treat toxoplasmosis in combination with a sulfonamide, and Vecamyl, used for moderately severe to severe essential hypertension and some cases of malignant hypertension. Phoenixus AG is a Switzerland-based biopharmaceutical company.
Major companies operating in the toxoplasmosis treatment drugs market are Sanofi SA, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Mylan NV, Sun Pharmaceutical Industries Ltd, Dr Reddys Laboratories Ltd, Amneal Pharmaceuticals Inc, Lupin Ltd, Alvogen Group Inc, Manus Aktteva Biopharma LLP, Cadila Healthcare Limited, Aurobindo Pharma Limited, Cipla Inc, Torrent Pharmaceuticals Ltd, Intas Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd, Jubilant Life Sciences, Zydus Lifesciences Ltd, Hetero Drugs Limited, Strides Pharma Science Limited, Alkem Laboratories Limited
North America was the largest region in the toxoplasmosis treatment drugs market in 2025. The regions covered in the toxoplasmosis treatment drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the toxoplasmosis treatment drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The toxoplasmosis treatment drug market consists of sales of clindamycin and atovaquone. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Toxoplasmosis Treatment Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses toxoplasmosis treatment drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for toxoplasmosis treatment drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The toxoplasmosis treatment drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drug Class: Pyrimethamine; Spiramycin; Leucovorin; Sulfadiazine; Folic Acid; Other Drug Class
2) By Indication: Chronic Toxoplasmosis Infection; Acute Toxoplasmosis Infection
3) By Route Of Administration: Parenteral; Oral
4) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
Subsegments:
1) By Pyrimethamine: Brand Name Variants; Combination Therapies
2) By Spiramycin: Brand Name Variants; Formulations
3) By Leucovorin: Dosage Forms; Combination Therapies
4) By Sulfadiazine: Brand Name Variants; Combination Therapies
5) By Folic Acid: Supplement Formulations; Combination Products With Other Drugs
6) By Other Drug Class: Atovaquone; Clindamycin; Trimethoprim-Sulfamethoxazole (TMP-SMX); Experimental Or Emerging Therapies
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Increased Research In Anti-Parasitic Drug Development
4.2.2 Rising Demand For Combination Therapies
4.2.3 Growth In Pediatric And Immunocompromised Patient Treatments
4.2.4 Expansion Of Hospital And Online Pharmacy Distribution Channels
4.2.5 Development Of Oral And Parenteral Formulations
5. Toxoplasmosis Treatment Drugs Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Clinics
5.3 Specialty Care Centers
5.4 Online Pharmacies
5.5 Retail Pharmacies
6. Toxoplasmosis Treatment Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Toxoplasmosis Treatment Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Toxoplasmosis Treatment Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Toxoplasmosis Treatment Drugs Market Size, Comparisons And Growth Rate Analysis
7.3. Global Toxoplasmosis Treatment Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Toxoplasmosis Treatment Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Toxoplasmosis Treatment Drugs Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9.3. Global Toxoplasmosis Treatment Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Parenteral, Oral
9.4. Global Toxoplasmosis Treatment Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.5. Global Toxoplasmosis Treatment Drugs Market, Sub-Segmentation Of Pyrimethamine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Brand Name Variants, Combination Therapies
9.6. Global Toxoplasmosis Treatment Drugs Market, Sub-Segmentation Of Spiramycin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Brand Name Variants, Formulations
9.7. Global Toxoplasmosis Treatment Drugs Market, Sub-Segmentation Of Leucovorin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Dosage Forms, Combination Therapies
9.8. Global Toxoplasmosis Treatment Drugs Market, Sub-Segmentation Of Sulfadiazine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Brand Name Variants, Combination Therapies
9.9. Global Toxoplasmosis Treatment Drugs Market, Sub-Segmentation Of Folic Acid, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Supplement Formulations, Combination Products With Other Drugs
9.10. Global Toxoplasmosis Treatment Drugs Market, Sub-Segmentation Of Other Drug Class, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Atovaquone, Clindamycin, Trimethoprim-Sulfamethoxazole (TMP-SMX), Experimental Or Emerging Therapies
10. Toxoplasmosis Treatment Drugs Market Regional And Country Analysis
10.1. Global Toxoplasmosis Treatment Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Toxoplasmosis Treatment Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Toxoplasmosis Treatment Drugs Market
12.1. China Toxoplasmosis Treatment Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Toxoplasmosis Treatment Drugs Market
13.1. India Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Toxoplasmosis Treatment Drugs Market
14.1. Japan Toxoplasmosis Treatment Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Toxoplasmosis Treatment Drugs Market
15.1. Australia Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Toxoplasmosis Treatment Drugs Market
16.1. Indonesia Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Toxoplasmosis Treatment Drugs Market
17.1. South Korea Toxoplasmosis Treatment Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Toxoplasmosis Treatment Drugs Market
19.1. South East Asia Toxoplasmosis Treatment Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Toxoplasmosis Treatment Drugs Market
20.1. Western Europe Toxoplasmosis Treatment Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Toxoplasmosis Treatment Drugs Market
21.1. UK Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Toxoplasmosis Treatment Drugs Market
22.1. Germany Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Toxoplasmosis Treatment Drugs Market
23.1. France Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Toxoplasmosis Treatment Drugs Market
24.1. Italy Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Toxoplasmosis Treatment Drugs Market
25.1. Spain Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Toxoplasmosis Treatment Drugs Market
26.1. Eastern Europe Toxoplasmosis Treatment Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Toxoplasmosis Treatment Drugs Market
27.1. Russia Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Toxoplasmosis Treatment Drugs Market
28.1. North America Toxoplasmosis Treatment Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Toxoplasmosis Treatment Drugs Market
29.1. USA Toxoplasmosis Treatment Drugs Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Toxoplasmosis Treatment Drugs Market
31.1. South America Toxoplasmosis Treatment Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Toxoplasmosis Treatment Drugs Market
32.1. Brazil Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Toxoplasmosis Treatment Drugs Market
33.1. Middle East Toxoplasmosis Treatment Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Toxoplasmosis Treatment Drugs Market
34.1. Africa Toxoplasmosis Treatment Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Toxoplasmosis Treatment Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Toxoplasmosis Treatment Drugs Market Regulatory and Investment Landscape
36. Toxoplasmosis Treatment Drugs Market Competitive Landscape And Company Profiles
